Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the breast and the uterus. Estrogen is a hormone in the body which helps in regulating the turnover (formation and destruction) of the bones. Reduction in the level of estrogen, mostly seen after menopause or immediately after the removal of the ovaries, results in loss of bone density and also weakened bones. This condition is known as osteoporosis. Raloxifene helps decrease the turnover of the bone and at the same time increase bone density, though not to the same extent as estrogen itself. As a result the bone becomes even stronger and prevents fractures in women with osteoporosis. Similarly, it also decreases low density lipoprotein (bad cholesterol or LDL) in the blood but it does not increase good cholesterol or HDL. It is also known to be used in reducing the risk of invasive breast cancer in certain women who have attained menopause.